Topical Betamethasone Valerate As a Prophylactic Agent to Prevent Acute Radiation Dermatitis in Head and Neck Malignancies: A Randomized, Open-Label, Phase 3 Trial

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(18)31999-8 ◽

2019 ◽

Vol 393 (10167) ◽

pp. 156-167 ◽

Cited By ~ 315

Author(s):

Ezra E W Cohen ◽

Denis Soulières ◽

Christophe Le Tourneau ◽

José Dinis ◽

Lisa Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Faculty of 1000 evaluation for Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718018463.793480272 ◽

2013 ◽

Author(s):

Sandra Nuyts

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70181-5 ◽

2013 ◽

Vol 14 (8) ◽

pp. 697-710 ◽

Cited By ~ 301

Author(s):

Jan B Vermorken ◽

Jan Stöhlmacher-Williams ◽

Irina Davidenko ◽

Lisa Licitra ◽

Eric Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018463.793481234 ◽

2013 ◽

Author(s):

Bruce Brockstein ◽

Nicholas Campbell

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32591-7 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1915-1928 ◽

Cited By ~ 230

Author(s):

Barbara Burtness ◽

Kevin J Harrington ◽

Richard Greil ◽

Denis Soulières ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Annals of Oncology ◽

10.1093/annonc/mdw376.68 ◽

2016 ◽

Vol 27 ◽

pp. vi350 ◽

Cited By ~ 5

Author(s):

A. Argiris ◽

M. Gillison ◽

R.L. Ferris ◽

K. Harrington ◽

T.K. Sanchez ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

USE OF XONRID® TO MANAGE RADIATION DERMATITIS IN BREAST AND HEAD AND NECK CANCERS: PRELIMINARY RESULTS OF A MONOCENTER AND OPEN LABEL, RANDOMIZED TRIAL

10.26226/morressier.5cdbe0ab618793e647b12afc ◽

2019 ◽

Author(s):

Ester Orlandi ◽

Nadia Facchinetti ◽

Letizia Ferella ◽

Nicola Alessandro Iacovelli ◽

Maria Carmen De Santis ◽

...

Keyword(s):

Randomized Trial ◽

Head And Neck ◽

Head And Neck Cancers ◽

Radiation Dermatitis ◽

Open Label ◽

Preliminary Results

Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006635.793477611 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356324.793557555 ◽

2019 ◽

Author(s):

Jose Biller

Keyword(s):

Acute Stroke ◽

Antiplatelet Therapy ◽

Standard Care ◽

Platelet Transfusion ◽

Cerebral Haemorrhage ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726438889.793525325 ◽

2016 ◽

Author(s):

Stefan Bielack

Keyword(s):

Open Label ◽

Phase 3 ◽